Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek, email him directly: derekb.lowe@gmail.com (mailto:derekb.lowe@gmail.com) ...

Eli Lilly and Company (LLY) reported third-quarter 2024 adjusted earnings per share (“EPS”) of $1.18, which missed the Zacks Consensus Estimate of $1.52 per share. In the year-ago quarter, the company had reported earnings of 10 cents per share.Adjusted earnings included an acquired in-process research and development (IPR&D) charge of $3.08 per share, primarily related to the acquisition of Morphic, which was closed in August.Revenues of $11.44 billion rose 20% year over year. Total revenues, however, miss ...

When looking for mistakes I made in the past, it is not difficult in more than 750 available articles about more than 100 different companies to find huge mistakes. Everybody is making mistakes – including me. And one articleMy analysis is focused on high-quality companies, that can outperform the market over the long-run due to a competitive advantage (economic moat) and high levels of defensibility. Focused on European and North American companies, but without constraints regarding market capitalization ( ...

Revenue Growth - Revenue for the three months ended September 30, 2024 increased by 20% to $11,439.1 million compared to $9,498.6 million in the same period in 2023[110] - Revenue for the nine months ended September 30, 2024 increased by 27% to $31,509.9 million compared to $24,770.7 million in the same period in 2023[110] - U.S. revenue for Q3 2024 increased by 46% to $7,813.6 million compared to $5,368.1 million in Q3 2023[130] - Outside U.S. revenue for Q3 2024 decreased by 12% to $3,625.5 million compared to $4,130.5 million in Q3 2023[130] - Consolidated revenue for Q3 2024 increased by 20% to $11,439.1 million compared to $9,498.6 million in Q3 2023[130] - U.S. revenue for the nine months ended September 30, 2024 increased by 39% to $21,343.2 million compared to $15,335.6 million in the same period in 2023[130] - Outside U.S. revenue for the nine months ended September 30, 2024 increased by 8% to $10,166.7 million compared to $9,435.0 million in the same period in 2023[130] - Consolidated revenue for the nine months ended September 30, 2024 increased by 27% to $31,509.9 million compared to $24,770.7 million in the same period in 2023[130] Net Income - Net income for the three months ended September 30, 2024 was $970.3 million, compared to a net loss of $57.4 million in the same period in 2023[110] - Net income for the nine months ended September 30, 2024 was $6,180.2 million, compared to $3,050.7 million in the same period in 2023[110] Product Development and Approvals - The company has approximately 50 new medicine candidates in clinical development or under regulatory review[112] - Tirzepatide (Mounjaro, Zepbound) Phase 3 trial for cardiovascular outcomes in type 2 diabetes is ongoing[113] - Insulin Efsitora Alfa Phase 3 trials for type 1 and type 2 diabetes met primary endpoints in 2024[113] - Donanemab was approved in the U.S. and Japan in 2024 for early Alzheimer's disease[114] - Jaypirca (Pirtobrutinib) was approved in the U.S. in 2023 for chronic lymphocytic leukemia and mantle cell lymphoma[116] - Imlunestrant Phase 3 trial for ER+HER2- metastatic breast cancer was announced positive in 2024[116] Product Revenue - Mounjaro U.S. revenue for the three months ended September 30, 2024 was $2.38 billion, a significant increase from $1.28 billion in the same period in 2023[135] - Mounjaro U.S. revenue for the nine months ended September 30, 2024 was $6.32 billion, compared to $2.73 billion in the same period in 2023[135] - Trulicity U.S. revenue decreased by 26% and 31% for the three and nine months ended September 30, 2024, respectively[135] - Verzenio U.S. revenue increased by 28% and 37% for the three and nine months ended September 30, 2024, respectively[137] - Zepbound U.S. revenue for the three and nine months ended September 30, 2024 was $1.26 billion and $3.02 billion, respectively[137] - Taltz U.S. revenue increased by 18% and 15% for the three and nine months ended September 30, 2024, respectively[137] Volume and Price Impact - Volume growth in the U.S. for Q3 2024 was 35%, driven by Zepbound and Mounjaro, partially offset by declines in Trulicity[131] - Price increases in the U.S. for Q3 2024 contributed 11% to revenue growth, driven by Humalog, Verzenio, and Trulicity[131] - Volume growth outside the U.S. for the nine months ended September 30, 2024 was 10%, primarily driven by Mounjaro and Verzenio[131] - Jardiance® subject to a 66% discount compared to 2023 U.S. calendar year list pricing for a 30-day supply under the Inflation Reduction Act[119] Financial Metrics - Gross margin as a percent of revenue increased by 0.6 percentage points and 2.3 percentage points for the three and nine months ended September 30, 2024, respectively[138] - Research and development expenses increased by 13% and 18% for the three and nine months ended September 30, 2024, respectively[138] - Marketing, selling, and administrative expenses increased by 16% and 13% for the three and nine months ended September 30, 2024, respectively[138] - Effective tax rate for the nine months ended September 30, 2024 was 19.1%, compared to 24.6% in the same period in 2023[139] - Acquired IPR&D charges for Q3 and nine months ended September 30, 2024 were primarily related to the acquisition of Morphic[141] - Net investment gains on equity securities were $(112.4) million for Q3 and $29.5 million for nine months ended September 30, 2024[141] - Effective tax rates were 38.9% for Q3 and 19.1% for nine months ended September 30, 2024[141] Cash and Debt - Cash and cash equivalents increased to $3.37 billion as of September 30, 2024, compared to $2.82 billion as of December 31, 2023[142] - Total debt increased to $31.12 billion as of September 30, 2024, up by $5.89 billion from December 31, 2023[142] - Company acquired Morphic for approximately $2.67 billion in Q3 2024, funded by debt issuance[142] Share Repurchase and Dividends - Company repurchased $521.1 million of shares under its $5.00 billion share repurchase program during nine months ended September 30, 2024[144] - Dividends paid during nine months ended September 30, 2024 totaled $3.51 billion, or $3.90 per share[144] - Company declared a Q4 2024 dividend of $1.30 per share, totaling approximately $1.17 billion[144] - Unused committed bank credit facilities totaled $8.42 billion as of September 30, 2024[144]

The big pharmaceutical company provided a disappointing Q3 update.Shares of Eli Lilly (LLY -6.45%) were sinking 6.3% lower as of 11:11 a.m. ET on Wednesday. The sharp decline came after the big drugmaker announced its third-quarter results before the market opened. Lilly reported Q3 revenue of $11.4 billion, up 20% year over year. However, the consensus projection among analysts surveyed by LSEG was for revenue of $12.1 billion.The company posted net income of $970.3 million, or $1.07 per share, based on ge ...

Eli Lilly (LLY) reported $11.44 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 20.4%. EPS of $1.18 for the same period compares to $0.10 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $12.03 billion, representing a surprise of -4.92%. The company delivered an EPS surprise of -22.37%, with the consensus EPS estimate being $1.52.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

Topline Drug maker Eli Lilly's share price plunged Wednesday morning after the company reported worse third-quarter results than expected, especially in its weight-loss drug division, registering a rare misstep for the Wall Street darling. Eli Lilly stock is on pace for its worst loss since 2000. Getty Images Key Facts Shares of Eli Lilly dropped about 14% within 15 minutes of market open, tumbling toward the worst daily percentage decline for the stock since the 31% loss suffered Aug. 9, 2000 and the third ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and onl ...

Eli Lilly (LLY) came out with quarterly earnings of $1.18 per share, missing the Zacks Consensus Estimate of $1.52 per share. This compares to earnings of $0.10 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -22.37%. A quarter ago, it was expected that this drugmaker would post earnings of $2.64 per share when it actually produced earnings of $3.92, delivering a surprise of 48.48%. Over the last four quarters, the company has ...

Eli Lilly (LLY) shares tumbled 10% after its third-quarter results fell well short of analysts' estimates before the bell Wednesday. The pharmaceutical giant registered $11.44 billion in revenue—above last year's $9.50 billion but below the $12.18 billion consensus estimate of analysts polled by Visible Alpha—as weight-loss drugs Mounjaro and Zepbound continue to boost Eli Lilly's sales. Lilly swung to a profit of $970.3 million, or $1.07 per share, but still well below the $1.69 billion and $1.87 per shar ...